PROTEIN-KINASE-C-ALPHA EXPRESSION IS REQUIRED FOR HEPARIN INHIBITION OF RAT SMOOTH-MUSCLE CELL-PROLIFERATION IN-VITRO AND IN-VIVO

Citation
Jm. Herbert et al., PROTEIN-KINASE-C-ALPHA EXPRESSION IS REQUIRED FOR HEPARIN INHIBITION OF RAT SMOOTH-MUSCLE CELL-PROLIFERATION IN-VITRO AND IN-VIVO, The Journal of biological chemistry, 271(42), 1996, pp. 25928-25935
Citations number
41
Categorie Soggetti
Biology
ISSN journal
00219258
Volume
271
Issue
42
Year of publication
1996
Pages
25928 - 25935
Database
ISI
SICI code
0021-9258(1996)271:42<25928:PEIRFH>2.0.ZU;2-J
Abstract
Heparin is a complex glycosaminoglycan that inhibits vascular smooth m uscle cell (SMC) growth in vitro and in vivo. To define the mechanism by which heparin exerts its antiproliferative effects, we asked whethe r heparin interferes with the activity of intracellular protein kinase C (PKC). The membrane-associated intracellular PKC activity increased following stimulation of cultured rat SMCs with fetal calf serum and was suppressed by heparin in a time- and dose-dependent manner, Hepari n acted through a selective inhibition of the PKC-alpha since preincub ation of the cells with a 20-mer phosphorothioate PKC-alpha antisense oligodeoxynucleotide (ODN) eliminated the heparin effect. In vivo, fol lowing balloon injury of the rat carotid artery, particulate fraction PKC content increased with a time course and to an extent comparable w ith the observed changes in vitro. Heparin, administered at the time o f injury or shortly thereafter, inhibited the activity of the particul ate PKC and suppressed the in situ phosphorylation of an 80-kDa myrist oylated alanine-rich protein kinase C substrate (MARCKS), a substrate of PKC, The topical application of the phosphorothioate antisense ODN selectively suppressed the expression of the PKC-alpha isoenzyme in vi vo but did not affect injury-induced myointimal proliferation. Topical application of the ODN also eliminated the antiproliferative activity of heparin. These results therefore suggest that heparin might block SMC proliferation by interfering with the PKC pathway through a select ive direct inhibition of the PKC-alpha isoenzyme.